On December 15, 2020 As Scandion Oncology A/S ("Scandion" or the "Company") reported that receives approximately SEK 236 million before issue costs from its rights issue (Press release, Scandion Oncology, DEC 15, 2020, View Source;supplement-to-previously-published-press-release-regarding-the-outcome-of-scandio,c3255229 [SID1234574543]). The issue costs amount to approximately SEK 36 million, which has been stated in the prospectus published by the Company on 24 November 2020. Hence, the Company receives net proceeds of approximately SEK 200 million from its rights issue.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!